Glipizide sustained release tablets and preparation method thereof
A technology of glipizide and sustained-release tablets, which is applied in the field of pharmaceuticals, can solve the problems of inability to release the drug stably for a long time, many times of administration, and high incidence of toxic and side effects, and achieve stable and effective blood drug concentration, increase residence time, The effect of reducing toxic side effects
Inactive Publication Date: 2011-06-29
SHANDONG FANGMING PHARMACEUTICAL CO LTD
View PDF1 Cites 4 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0009] The technical problem to be solved in the present invention is to disclose a sustained-release tablet containing glipizide, so as to overcome the problems in the prior art that the drug cannot be released stably for a long time in the body, the number of administrations is high, and the incidence of toxic and side effects is high. to improve patient safety and compliance
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0021] Glipizide 5g
[0022] Hypromellose (K4M) 46g
[0023] 36g pregelatinized starch
[0024] Microcrystalline Cellulose 70g
[0025] 80% ethanol appropriate amount
[0027]
[0028] Makes 1000 pieces
Embodiment 2
[0030] Glipizide 5g
[0031] Hypromellose (K4M) 46g
[0032] Pregelatinized starch 56g
[0033] Microcrystalline Cellulose 50g
[0034] 85% ethanol appropriate amount
[0036]
[0037] Makes 1000 pieces
Embodiment 3
[0039] Glipizide 5g
[0040] Hypromellose (K4M) 46g
[0041] Microcrystalline Cellulose 104g
[0042] 85% ethanol appropriate amount
[0044]
[0045] Makes 1000 pieces
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention discloses a prescription of glipizide sustained release tablets. The prescription comprises the following components in percentage by weight: 0.02-0.2% of glipizide, 20-30% of sustained-release matrix material, 65.8-78.48% of disintegrating agent and filling agent, a proper amount of wetting agent and 0.5-4.0% of lubricating agent. The glipizide sustained release tablets disclosed by the invention are clinically used for treating mild-moderate type II diabetes, and can realize stable drug release and maintain blood concentration for a long time after oral administration, thus reducing administration times and greatly improving medication safety and compliance of a patient. The glipizide sustained release tablets disclosed by the invention have the advantages of simple preparation process, applicability to large-scale industrial production and wide application prospects.
Description
technical field [0001] The invention relates to a preparation method of a slow-release tablet containing glipizide, which belongs to the technical field of medicines. Background technique [0002] Glipizide is a colorless, odorless white powder, insoluble in water and ethanol, with a pKa of 5.9. Its English name is Glipizide, and its chemical name is 1-cyclohexyl-3-{4-[2-(5-methylpyrazine-2-amide)-ethyl]benzenesulfonyl}urea. Its structural formula is as follows: [0003] [0004] Molecular formula: C21H27N5O4S, molecular weight: 445.54 [0005] Glipizide is a second-generation sulfonylurea oral hypoglycemic drug, which can promote the secretion of insulin by pancreatic β cells and enhance the effect of insulin on target tissues; it can also stimulate pancreatic α cells to inhibit glucagon secretion. Inhibit liver glycogen breakdown, promote muscle utilization and consumption of glucose. Clinically, it is mainly used for patients with mild to moderate non-insulin-depen...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K9/22A61K31/64A61K47/38A61P3/10
Inventor 孟爱红崔改英穆子齐苏贵勇
Owner SHANDONG FANGMING PHARMACEUTICAL CO LTD
